SOCIOECONOMIC VALUE OF OCRELIZUMAB IN THE TREATMENT OF PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS

被引：0
|
作者：
Di Maio, D. [1 ]
Liu, C. [1 ]
Marcelli, G. [1 ]
Alvarez, Sanchez J. [1 ]
Overell, J. [1 ]
机构：
[1] F Hoffman La Roche Ltd, Basel, Switzerland
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND47
引用
收藏
页码：S631 / S631
页数：1
相关论文
共 50 条
  • [1] SOCIOECONOMIC VALUE OF OCRELIZUMAB IN THE TREATMENT OF PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS
    Di Maio, D.
    Wu, J.
    Stavropoulos, A.
    Alvarez, Sanchez J.
    Diles, D.
    VALUE IN HEALTH, 2021, 24 : S166 - S166
  • [2] SOCIOECONOMIC VALUE OF OCRELIZUMAB IN THE TREATMENT OF PATIENTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS
    Di Maio, D.
    Wu, J.
    Stavropoulos, A.
    Sanchez, Alvarez J.
    Diles, D.
    VALUE IN HEALTH, 2021, 24 : S161 - S161
  • [3] SOCIOECONOMIC VALUE OF OCRELIZUMAB IN THE TREATMENT OF PATIENTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS
    Di Maio, D.
    Liu, C.
    Marcelli, G.
    Alvarez, Sanchez J.
    Overell, J.
    VALUE IN HEALTH, 2020, 23 : S632 - S633
  • [4] Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis
    Menge, Til
    Dubey, Divyanshu
    Warnke, Clemens
    Hartung, Hans-Peter
    Stuve, Olaf
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2016, 16 (10) : 1131 - 1139
  • [5] Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis
    Benjamin Turner
    Bruce A. C. Cree
    Ludwig Kappos
    Xavier Montalban
    Caroline Papeix
    Jerry S. Wolinsky
    Regine Buffels
    Damian Fiore
    Hideki Garren
    Jian Han
    Stephen L. Hauser
    Journal of Neurology, 2019, 266 : 1182 - 1193
  • [6] Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis
    Turner, Benjamin
    Cree, Bruce A. C.
    Kappos, Ludwig
    Montalban, Xavier
    Papeix, Caroline
    Wolinsky, Jerry S.
    Buffels, Regine
    Fiore, Damian
    Garren, Hideki
    Han, Jian
    Hauser, Stephen L.
    JOURNAL OF NEUROLOGY, 2019, 266 (05) : 1182 - 1193
  • [7] Cost-effectiveness of ocrelizumab for treatment of Iranian patients with relapsing multiple sclerosis
    Ayati, Nayyereh
    Taheri, Saeed
    Sahraian, Mohammad Ali
    Nikfar, Shekoufeh
    CURRENT JOURNAL OF NEUROLOGY, 2021, 20 (03): : 154 - 161
  • [8] Comparison of cognitive functions in relapsing and progressive multiple sclerosis patients on ocrelizumab treatment
    Ozakbas, S.
    Ozcelik, S.
    Kaya, E.
    Ozdogar, T.
    Sagici, O.
    Baba, C.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (2_SUPPL) : 9 - 9
  • [9] Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis
    Hauser, Stephen L.
    Kappos, Ludwig
    Montalban, Xavier
    Craveiro, Licinio
    Chognot, Cathy
    Hughes, Richard
    Koendgen, Harold
    Pasquarelli, Noemi
    Pradhan, Ashish
    Prajapati, Kalpesh
    Wolinsky, Jerry S.
    NEUROLOGY, 2021, 97 (16) : E1546 - E1559
  • [10] Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis
    Singer, B.
    Ross, A. P.
    Tobias, K.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2011, 65 (08) : 887 - 895
12345